Welcome to our dedicated page for Relay Therapeutics news (Ticker: RLAY), a resource for investors and traders seeking the latest updates and insights on Relay Therapeutics stock.
Relay Therapeutics, Inc. develops clinical-stage small molecule precision medicines for cancer and genetic disease. The company uses its Dynamo® platform, which combines computational and experimental approaches to drug protein targets that have been intractable or inadequately addressed.
Recurring RLAY news centers on zovegalisib (RLY-2608), a mutant-selective PI3Kα inhibitor studied in HR+/HER2- metastatic breast cancer and PI3Kα-driven vascular anomalies. Company updates also cover pipeline programs for NRAS-driven solid tumors and Fabry disease, clinical and regulatory data presentations, operating results, capital-structure matters, license or collaboration agreements, and governance developments.
Relay Therapeutics (Nasdaq: RLAY) has announced a collaboration with Foundation Medicine to develop FoundationOne®CDx as a companion diagnostic for RLY-4008, an investigational FGFR2 inhibitor targeting cholangiocarcinoma. Interim clinical data presented at ESMO 2022 showed an 88% overall response rate in patients with FGFR2 mutations. The partnership aims to enable more effective treatments for patients with aggressive conditions, expanding access to precision medicine.
Relay Therapeutics (Nasdaq: RLAY) announced promising interim clinical results for RLY-4008, a selective FGFR2 inhibitor, achieving an 88% overall response rate in FGFRi-naïve FGFR2-fusion cholangiocarcinoma patients. Data were presented at the ESMO Congress, reflecting results from 17 patients as of August 1, 2022. The pivotal cohort enrollment is expected to wrap up in the second half of 2023. The company is also gearing up to reveal further data on RLY-2608, a pan-mutant selective PI3Kα inhibitor, within the next year.
Relay Therapeutics announced that an interim clinical data abstract for RLY-4008 has been selected for an oral presentation at the ESMO Congress on September 11, 2022. The focus will be on dose escalation in patients with FGFR2 fusion cholangiocarcinoma. The company will hold a conference call on September 12, 2022, at 8:00 am E.T. to discuss these results. RLY-4008 is a selective oral inhibitor of FGFR2, showing preclinical efficacy against cancer cell lines and is presently under evaluation in a clinical trial for advanced FGFR2-altered solid tumors.
Relay Therapeutics (Nasdaq: RLAY) reported its Q2 2022 financial results, revealing a net loss of $76.8 million, down from $193.4 million in Q2 2021, with a net loss per share of $0.71. The company appointed Dr. Sekar Kathiresan to its board, enhancing its leadership with his extensive experience in genetics and cardiovascular disease. Relay continues to advance its drug pipeline, particularly RLY-2608 and RLY-4008, with key clinical developments anticipated in the coming months, aiming for a strong momentum in their breast cancer and tumor agnostic portfolios.
Relay Therapeutics (Nasdaq: RLAY) announced plans to report its Q2 2022 financial results and corporate highlights after market close on August 4, 2022. The company specializes in precision medicine, leveraging its Dynamo™ platform to enhance drug discovery processes, particularly in oncology and genetic disease treatment.
Relay Therapeutics aims to revolutionize drug development through advanced computational and experimental technologies, focusing on previously challenging protein targets.
Relay Therapeutics has announced key developments regarding RLY-4008, following a productive end-of-phase 1 meeting with the FDA. The company plans a single-arm trial for FGFR2-fusion cholangiocarcinoma, potentially facilitating accelerated approval. Interim data revealed a 62% confirmed partial response rate among FGFRi-naïve patients treated with a 70 mg dose. Additionally, Relay introduced three new programs targeting HR+/HER2- breast cancer and confirmed adequate funding to sustain operations through 2025.
Relay Therapeutics, a clinical-stage precision medicine company, has announced that registration is now open for its virtual analyst and investor event scheduled for June 27, 2022. The event will run from 8:00 a.m. to 9:00 a.m. ET and will be accessible via the company’s website. Relay Therapeutics aims to innovate drug discovery through its advanced Dynamo™ platform, targeting oncology and genetic diseases. The company focuses on developing transformative therapies utilizing unique computational and experimental technologies.
Relay Therapeutics (Nasdaq: RLAY) will participate in two upcoming fireside chats: the Cowen 3rd Annual Oncology Innovation Summit on June 2, 2022, at 11:30 a.m. ET and the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022, at 5:40 p.m. ET. Both events will be webcast live, accessible via Relay Therapeutics' website, and archived for 30 days post-event. The company focuses on precision medicines, integrating advanced computational and experimental technologies to enhance drug discovery in oncology and genetic disease.
Relay Therapeutics (Nasdaq: RLAY) reported its first quarter 2022 financial results, showing a net loss of $62.0 million or $0.57 per share, up from a net loss of $42.2 million in Q1 2021. As of March 31, 2022, the company held approximately $898 million in cash and equivalents, sufficient to support operations into 2025. Notable achievements include the initiation of the combination arm for RLY-2608 and continued enrollment for RLY-4008 expansion cohorts. The company anticipates releasing initial clinical data for RLY-2608 in H1 2023.
Relay Therapeutics (Nasdaq: RLAY) announced participation in a fireside chat at the Bank of America Securities 2022 Healthcare Conference on May 10, 2022, at 3:20 p.m. PT in Las Vegas, NV. The chat will be broadcast live via their website and can be accessed under the Events section. An archived replay will be available for 30 days post-event. Relay Therapeutics focuses on precision medicines, leveraging its Dynamo™ platform for drug discovery in oncology and genetic diseases.